Skip to content

    How does a GLP-1 prescription fit with a DPP-4 inhibitor?

    How does a GLP-1 prescription fit with a DPP-4 inhibitor?

    Your diabetes medicine list already includes a daily tablet. Now another clinician has mentioned a GLP-1 medicine for blood sugar or weight care. Should both stay on the list?

    That's a question for the clinicians who know your treatment, and it's a good one to ask before a new prescription begins. DPP-4 inhibitors and GLP-1 medicines affect related systems. Understanding that connection can make the medication review less confusing.

    First, identify the medicines

    DPP-4 inhibitors are a group of oral medicines used for type 2 diabetes. Examples include sitagliptin and linagliptin. Your prescription may be a single medicine or a combination tablet, so the name on the bottle matters.

    GLP-1 receptor agonists include medicines such as semaglutide and liraglutide. They are used for different purposes depending on the product and the person's circumstances. Tirzepatide works on both GIP and GLP-1 receptors and is a related but distinct type of medicine.

    Brand names and product formulations can be confusing. Bring the bottles, an up-to-date pharmacy list, or photos of the labels. Include medicines prescribed by other clinicians and any you take less often. Don't assume a clinician can see every prescription in another office's system.

    What is the connection?

    After you eat, your body releases hormones involved in blood sugar regulation. GLP-1 is one of those signals. DPP-4 is an enzyme that breaks down certain hormones, including naturally occurring GLP-1. A DPP-4 inhibitor reduces that breakdown; a GLP-1 receptor agonist acts on the GLP-1 receptor.

    That is a simplified description, but it explains why the medicines are discussed together. They approach a related pathway in different ways. The fact that two products have different names doesn't necessarily mean that combining them will add useful benefit.

    Are they generally used together?

    Current diabetes treatment guidance does not recommend routinely using a DPP-4 inhibitor at the same time as a GLP-1 receptor agonist or a dual GIP/GLP-1 medicine. The reason given is that the combination does not provide additional glucose lowering beyond the GLP-1-based treatment.

    That is general guidance, not an instruction to change your own medication list. If both appear on your list, don't stop either one on your own. Contact the prescriber or pharmacist, explain exactly what you take, and ask them to clarify the plan. A list can be outdated, and a combination tablet can make a change more complicated than it first appears.

    Why a combination tablet matters

    Some tablets contain more than one active ingredient. If you recognize the DPP-4 ingredient in a combination product, don't assume that the entire tablet should be discarded or that you should replace one part yourself. The other ingredient may still be an important part of your diabetes care.

    Ask: “This bottle contains more than one medicine. If our plan changes, what happens to the other ingredient?” Your clinician can review the actual product and give you written directions. A pharmacist can help you identify the ingredients if the label is hard to interpret.

    The same principle applies to refill lists in an app. An old entry may remain visible after treatment changes, while a current medication may be missing. Review what you are actually taking, not only what appears on the screen.

    Ask about the rest of your diabetes plan

    The DPP-4 question is only one part of the visit. Tell the team about all medicines you take, how you monitor glucose, any recent low or high readings, and symptoms that concern you. Ask what to do if nausea or vomiting makes it difficult to eat, drink or keep an oral medicine down.

    Some diabetes medicines carry a risk of low blood sugar, especially in particular combinations. The risk and any changes depend on your complete treatment plan. Ask your clinician what signs to watch for and what your personal low-blood-sugar plan is; don't create a new dosing schedule from an article.

    It's also reasonable to ask about cost, access and follow-up. If one clinician starts a new medicine, who will update the pharmacy list? Who will review your readings? When should you check in if the prescription isn't available?

    Leave with a clear, written answer

    Before ending the conversation, repeat back the plan in your own words. You might ask the team to list each medicine, what it is for, and whether anything has changed. If the instructions from two offices differ, ask them to coordinate before you act.

    The useful takeaway is that DPP-4 inhibitors and GLP-1-based treatments overlap in how they relate to incretin signaling, and using them together is generally not recommended for additional glucose lowering. Your care team can translate that general point into a safe plan for your particular prescriptions.